PD-L1 Expression and IO Therapy in Lung and Breast Cancer
A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.
EP: 1.Available Molecular Tests for Solid Tumors
EP: 2.Using Molecular Testing to Guide Treatment Decisions
Now Viewing
EP: 3.PD-L1 Expression and IO Therapy in Lung and Breast Cancer
EP: 4.Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer
EP: 5.Currently Targetable Mutations in Lung and Breast Cancer
EP: 6.Choosing a Molecular Testing Panel for Solid Tumors
EP: 7.Biomarker Testing Interpretation in Breast and Lung Cancer
EP: 8.Challenges of Biomarker Testing in Breast Cancer
EP: 9.Use of Liquid Biopsies in Breast Cancer
EP: 10.Discussing Biomarker Testing with Patients
EP: 11.Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer
EP: 12.Clinical Scenario: A 74-Year-Old Man with Lung Cancer
EP: 13.Further Molecular Testing in Early-Stage Metastatic Breast Cancer
EP: 14.Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations
EP: 15.Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer
EP: 16.Biomarker Testing Standards-of-Care in Breast and Lung Cancer
Related Videos
Related Content
